Home » Stocks » LEXX

Lexaria Bioscience Corp. (LEXX)

Stock Price: $6.10 USD -0.12 (-1.93%)
Updated May 11, 2021 9:32 AM EDT - Market open
Market Cap 31.35M
Revenue (ttm) 702,824
Net Income (ttm) -2.37M
Shares Out 5.10M
EPS (ttm) -1.05
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 11
Last Price $6.10
Previous Close $6.22
Change ($) -0.12
Change (%) -1.93%
Day's Open -
Day's Range 6.09 - 6.10
Day's Volume 27,222
52-Week Range 3.98 - 9.46

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Phoenix, Arizona--(Newsfile Corp. - May 7, 2021) - The Stock Day Podcast welcomed Lexaria Bioscience Corp. (NASDAQ: LEXX) ("the Company"), a company with a proprietary drug delivery technology, DehydraT...

4 days ago - Newsfile Corp

Up to 2,178% more CBD delivered into bloodstream* Up to 1,737% more CBD delivered into brain tissue* KELOWNA, BC / ACCESSWIRE / May 6, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (CSE:L...

5 days ago - Accesswire

Vancouver, British Columbia--(Newsfile Corp. - April 27, 2021) - Lexaria Bioscience Corp. (CSE: LXX) (NASDAQ: LEXX) - Chris Bunka, CEO and Chairman of Lexaria Bioscience, speaks about the Company's prop...

1 week ago - Newsfile Corp

Lexaria Bioscience Corp (CSE:LXX) (OTCMKTS:LXRP) revealed that its first human clinical trial assessing its DehydraTECH CBD technology to treat high blood pressure - HYPER-H21-1 - is now officially unde...

2 weeks ago - Proactive Investors

Study to examine DehydraTECHTM CBD's ability to control blood pressure First of three human clinical studies hoped to validate Lexaria's patented technology for hypertension relief KELOWNA, BC / ACCESSW...

2 weeks ago - Accesswire

KELOWNA, BC / ACCESSWIRE / April 15, 2021 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces the appoi...

3 weeks ago - Accesswire

New York, New York--(Newsfile Corp. - April 15, 2021) -  PCG Digital -- Hypertension, or high blood pressure, is known as the "silent killer" because it causes more than 7 million deaths each year-often...

3 weeks ago - Newsfile Corp

Lexaria Bioscience Corp (NASDAQ:LEXX) (CSE:LXX) announced that its corporate client Amari Corp's "Everyday Calm" CBD product was named a Top CBD Product Pick by New Hope Network, host of the industry-le...

3 weeks ago - Proactive Investors

DehydraTECHTM Powers Amari's Award-Winning Products KELOWNA, BC / ACCESSWIRE / April 14, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innov...

3 weeks ago - Accesswire

New York, New York--(Newsfile Corp. - April 8, 2021) -  PCG Digital -- The team at Lexaria Bioscience (NASDAQ: LEXX), a leader in cannabinoid research, has been thinking outside the box. Utilizing Dehyd...

1 month ago - Newsfile Corp

Lexaria Bioscience Corp (NASDAQ:LEXX) (CSE:LXX), a global innovator in drug delivery platforms, said Tuesday it will begin important new applied research and development study programs.   In a statement...

1 month ago - Proactive Investors

Undertaking new 2021 R&D programs in additional drug markets with combined market potential of $87 Billion. KELOWNA, BC / ACCESSWIRE / April 6, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW...

1 month ago - Accesswire

Lexaria Bioscience Corp (NASDAQ:LEXX) (CSE:LXX) shared Wednesday positive results from its extended stability testing, which showed unparalleled stability for bottled CBD drinks made using its technolog...

1 month ago - Proactive Investors

DehydraTECHTM CBD-Beverage Demonstrates 93.4% Potency One Year After Production Lexaria's Nanoemulsification Processing Technique Ensures Content Uniformity and Homogeneity of CBD Distribution Without N...

1 month ago - Accesswire

Lexaria Bioscience Corp (NASDAQ:LEXX) (CSE:LXX) (OTCMKTS:LXR) announced Tuesday extensive progress in two of the four planned antiviral drug studies in its 2021 applied research and development (R&D) pr...

1 month ago - Proactive Investors

10.30am: Proactive North America headlines: Neo Lithium Corp (CVE:NLC) (OTCQX:NTTHF) (FRA:NE2) closes its C$2.6M equity financing with Chinese investor CATL GlobeX Data Ltd (OTCQB:SWISF) (CSE:SWIS) rece...

Other stocks mentioned: CYDY, FTSSF, GTBAF, HERTF, JGLDF, LMLLF, NTTHF ...
1 month ago - Proactive Investors

Two of the four planned studies progressing to examine DehydraTECH™ with antivirals targeting SARS-CoV-2 / COVID-19 . KELOWNA, BC / ACCESSWIRE / March 16, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(N...

1 month ago - Accesswire

Lexaria Bioscience Corp (CSE:LXX) (OTCMKTS:LXRP) has updated investors on the progress of assessing its DehydraTECH CBD technology in treating high blood pressure, noting that all five of its planned st...

1 month ago - Proactive Investors

Five studies underway to examine DehydraTECHTM CBD for Hypertension. KELOWNA, BC / ACCESSWIRE / March 15, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"...

1 month ago - Accesswire

Lexaria recently expanded its hypertension R&D program evaluating effectiveness of DehydraTECH-processed CBD to three human clinical studies and two animal studies KELOWNA, BC / ACCESSWIRE / March 11, 2...

2 months ago - Accesswire

Novel drug delivery platform DehydraTECH masks unwanted tastes, improves onset speed, increases bioavailability of active ingredients Cannabis is the current focus, but company eyeing massive markets su...

2 months ago - Proactive Investors

VANCOUVER, BC, Feb. 16, 2021 /PRNewswire/ - Lexaria Bioscience's (NASDAQ: LEXX) (CSE: LEXX) drug delivery technology, DehydraTECHTM improves the "bioavailability" of pharmaceutical ingredients. "Bioavai...

2 months ago - PRNewsWire

Lexaria Bioscience Corp (NASDAQ:LEXX) (CSE:LXX) is expanding its applied research and development (R&D) program in 2021 with a particular focus on DehydraTECH-enabled CBD for hypertension, the company a...

2 months ago - Proactive Investors

New York, New York--(Newsfile Corp. - February 9, 2021) - PCG Digital - Chris Bunka is a happy man. As CEO of Lexaria Bioscience (NASDAQ: LEXX) since 2006, he's battled to legitimize cannabinoids as a m...

3 months ago - Newsfile Corp

Phoenix, Arizona--(Newsfile Corp. - January 28, 2021) - The Stock Day Podcast welcomed Lexaria Bioscience Corp. (NASDAQ: LEXX) (CSE: LXX) ("the Company"), a company with the proprietary drug delivery te...

3 months ago - Newsfile Corp

KELOWNA, BC / ACCESSWIRE / January 15, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to ann...

3 months ago - Accesswire

KELOWNA, BC / ACCESSWIRE / January 15, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company") today announced the closing of its previously announced underwritten public of...

3 months ago - Accesswire

KELOWNA, BC / ACCESSWIRE / January 12, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company") today announced that its common stock and warrants will begin trading on the N...

3 months ago - Accesswire

About LEXX

Lexaria Bioscience Corp. operates in the drug delivery platform business. It develops and out-licenses its DehydraTECH technology for the delivery of bioactive compounds that promotes healthy ingestion methods, lower overall dosing, and higher effectiveness in active molecule delivery. The company has licensed DehydraTECH to various companies operating in the nicotine, pharmaceutical, nutraceutical, and vitamin industries. Lexaria Bioscience Corp. was founded in 2004 and is headquartered in Kelowna, Canada.

Industry
Packaged Foods
Founded
2004
Stock Exchange
NASDAQ
Ticker Symbol
LEXX
Full Company Profile

Financial Performance

In 2020, LEXX's revenue was $384,543, an increase of 72.74% compared to the previous year's $222,610. Losses were -$4.08 million, -1.77% less than in 2019.

Financial Statements